Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00688415 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00688415 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 33 participants.
The verdict
NCT00688415, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a multi-center, Phase I study of a new investigational drug, VTX-2337, that may stimulate the immune system to help fight cancer. The purpose of the study is to assess the safety of the investigational drug and to identify the highest dose that is well-tolerated. The pharmacology of VTX-2337 will also be evaluated.
Interventions
- DRUG VTX-2337
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2008-11-07 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00688415
The ClinicalTrials.gov registry entry for NCT00688415 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VTX-2337 is the first listed.
NCT00688415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00688415 about?
NCT00688415 is a clinical study titled "Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer". This is a multi-center, Phase I study of a new investigational drug, VTX-2337, that may stimulate the immune system to help fight cancer. The purpose of the study is to assess the safety of the investigational drug and to identify the highest dose that is well-tolerated. The pharmacology of VTX-2337...
What is the current status of trial NCT00688415?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2008-11-07. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00688415?
The interventions under investigation include: VTX-2337 (DRUG).
Who is sponsoring clinical trial NCT00688415?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.